DermTech Analysis
| DMTKDelisted Stock | USD 0.04 0.02 71.36% |
DermTech is overvalued with Real Value of 0.0347 and Hype Value of 0.0365. The main objective of DermTech delisted stock analysis is to determine its intrinsic value, which is an estimate of what DermTech is worth, separate from its market price. There are two main types of DermTech's stock analysis: fundamental analysis and technical analysis.
The DermTech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
DermTech |
DermTech Stock Analysis Notes
About 18.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.02. Some equities with similar Price to Book (P/B) outperform the market in the long run. DermTech recorded a loss per share of 2.65. The entity last dividend was issued on the 30th of August 2019. The firm had 1:2 split on the 30th of August 2019. DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. The company sells its products primarily to pathology and oncology practitioners. Dermtech operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 255 people. To learn more about DermTech call John MD at 858 450 4222 or check out https://www.dermtech.com.DermTech Investment Alerts
| DermTech is not yet fully synchronised with the market data | |
| DermTech has some characteristics of a very speculative penny stock | |
| DermTech has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.3 M. Net Loss for the year was (100.89 M) with profit before overhead, payroll, taxes, and interest of 647 K. | |
| DermTech currently holds about 173.79 M in cash with (76.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
DermTech Upcoming and Recent Events
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
DermTech Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.29 M.DermTech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DermTech insiders, such as employees or executives, is commonly permitted as long as it does not rely on DermTech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DermTech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sun Kevin M over six months ago Disposition of 445 shares by Sun Kevin M of DermTech at 0.34 subject to Rule 16b-3 | ||
Akhavan Ramin over six months ago Disposition of 1757 shares by Akhavan Ramin of DermTech at 0.31 subject to Rule 16b-3 | ||
Sun Kevin M over six months ago Disposition of 2530 shares by Sun Kevin M of DermTech at 0.31 subject to Rule 16b-3 | ||
Todd Wood over six months ago Acquisition by Todd Wood of 85114 shares of DermTech subject to Rule 16b-3 | ||
Sun Kevin M over six months ago Disposition of 445 shares by Sun Kevin M of DermTech at 0.7 subject to Rule 16b-3 | ||
Sun Kevin M over six months ago Disposition of 2531 shares by Sun Kevin M of DermTech at 0.88 subject to Rule 16b-3 | ||
Sun Kevin M over a year ago Sale by Sun Kevin M of 223 shares of DermTech | ||
Sun Kevin M over a year ago Sale by Sun Kevin M of 514 shares of DermTech | ||
Sun Kevin M over a year ago Sale by Sun Kevin M of 198 shares of DermTech |
DermTech Outstanding Bonds
DermTech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. DermTech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most DermTech bonds can be classified according to their maturity, which is the date when DermTech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About DermTech Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how DermTech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling DermTech shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as DermTech. By using and applying DermTech Stock analysis, traders can create a robust methodology for identifying DermTech entry and exit points for their positions.
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. The company sells its products primarily to pathology and oncology practitioners. Dermtech operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 255 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding DermTech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Companies Directory Now
Companies DirectoryEvaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |
| All Next | Launch Module |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in DermTech Stock
If you are still planning to invest in DermTech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DermTech's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |